STOCK TITAN

Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is set to participate in upcoming events like TD Cowen's 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference. The company will engage in Fireside Chat Presentations on March 6 and March 13, 2024, respectively. Interested parties can access presentation materials on the Arrowhead website.
Positive
  • None.
Negative
  • None.

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

TD Cowen's 44th Annual Health Care Conference – March 6, 2024

Type: Fireside Chat Presentation
Date: March 6, 2024
Time: 9:10 a.m. ET

Leerink Partners Global Biopharma Conference – March 13, 2024

Type: Fireside Chat Presentation
Date: March 13, 2024
Time: 8:00 a.m. ET

Presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma or on LinkedIn. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.

Vince Anzalone, CFA

626-304-3400

ir@arrowheadpharma.com

Investors:

LifeSci Advisors, LLC

Brian Ritchie

212-915-2578

britchie@lifesciadvisors.com

www.lifesciadvisors.com

Media:

LifeSci Communications, LLC

Jason Braco, Ph.D.

646-751-4361

jbraco@lifescicomms.com

www.lifesciadvisors.com

Source: Arrowhead Pharmaceuticals, Inc.

FAQ

When is Arrowhead Pharmaceuticals, Inc. (ARWR) scheduled to participate in TD Cowen's 44th Annual Health Care Conference?

Arrowhead Pharmaceuticals, Inc. (ARWR) is scheduled to participate in TD Cowen's 44th Annual Health Care Conference on March 6, 2024.

What type of presentation will Arrowhead Pharmaceuticals, Inc. (ARWR) engage in at the Leerink Partners Global Biopharma Conference?

Arrowhead Pharmaceuticals, Inc. (ARWR) will participate in a Fireside Chat Presentation at the Leerink Partners Global Biopharma Conference.

Where can interested parties access presentation materials for Arrowhead Pharmaceuticals, Inc. (ARWR) events?

Interested parties can access presentation materials on the Events and Presentations page under the Investors section of the Arrowhead website.

Arrowhead Research Corporation

NASDAQ:ARWR

ARWR Rankings

ARWR Latest News

ARWR Stock Data

2.44B
118.74M
4.47%
79.71%
7.6%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PASADENA